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ABSTRACT 
Background: Many Japanese patients with hepatic disorders confirmed on 
diagnostic imaging and coexisting upper gastrointestinal (GO peptic lesions 
receive treatment with proton pump inhibitors. Some pharmacotherapies used 
to treat peptic ulcers have been associated with adverse drug reactions (ADRs), 
including elevated liver enzyme levels. 
Accepted for publication December 27, 2005. 
Reproduction in whole or part is not permitted. 
doi:l 0.1016/j.cu rtheres.2006.02.003 
0011-393X/06/$19.00 
Copyright © 2006 Excerpta Medica, Inc. 1 
CURRENT THERAPEUTIC RESEARCH 
Objective: The aim of this study was to determine the tolerability and effec- 
tiveness of rabeprazole sodium in treating peptic lesions in patients with coex- 
isting hepatic disorders. 
Methods: This open-label, practice-based, postmarketing surveillance inves- 
tigation was conducted at 15 centers across Japan. Male and female patients 
aged >18 years with peptic lesions confirmed on upper GI endoscopy and with 
underlying hepatic disease were enrolled. Patients were randomly assigned to 
receive rabeprazole 10 or 20 mg PO (tablet) QD after a meal for up to 8 weeks. 
Tolerability was assessed using monitoring of the incidence of ADRs deter- 
mined by direct patient questioning, spontaneous reporting, and laboratory 
assessment. All patients who received at least 1 dose of study drug were 
included in the tolerability assessment. Effectiveness was assessed at baseline 
and study end using the rates of achievement of improvement on endoscopy, 
relief of subjective/objective symptoms (rates of improvement in epigastric 
pain and heartburn), and global improvement. The effectiveness analysis 
included all patients with complete data before and after treatment. Sub- 
analyses were conducted to determine the effectiveness of drug by identifica- 
tion of the proportion of patients with coexisting hepatic disorders (cirrhosis, 
chronic hepatitis, and other hepatic diseases [eg, alcoholic hepatitis, fatty 
liver[) and by peptic lesion (gastric ulcer, duodenal ulcer, stomal ulcer, and 
reflux esophagitis) who achieved improvement. 
Results: A total of 114 patients were enrolled; 108 patients were included in 
the tolerability analysis (81 men, 27 women; mean age, 59.9 years; 10-mg dose, 
90 patients; 20-mg dose, 18 patients) and 98 patients were included in the analysis 
of effectiveness. Twenty-one ADRs occurred in 11 (10.2%) patients. Serious 
ADRs occurred in 2 patients (elevated bilirubin level and hepatic encephalopa- 
thy, 1 patient each). Administration of rabeprazole was discontinued in 5 pa- 
tients due to the occurrence of the following ADRs: constipation (1 patient); 
epigastric pain (1); dyslalia, disorientation, tremor, sleep disorder, and hepatic 
encephalopathy (1); diarrhea (1); and elevated alkaline phosphatase and y-glutamyl 
transpeptidase levels (1). On endoscopy, the proportion of patients achieving 
improvement with either dose was 30/33 (90.9%). The relief rates assessed 
using subjective symptoms were 47/55 (85.5%) and 47/56 (83.9%) for epigastric 
pain and heartburn, respectively. The proportion of patients achieving lobal 
improvement with either dose was 80/98 (81.6%) patients (49/62 [79.0%[ for 
cirrhosis, 11/16 [68.8%] for chronic hepatitis, and 20/20 [100.0%] for other 
hepatic diseases [alcoholic hepatitis, fatty liver]). 
Conclusion: In this study in Japanese patients with hepatic disorders, rabe- 
prazole was well tolerated and appeared effective for the treatment of upper 
GI peptic lesions. (Curr Ther Res Clin Exp. 2006;67:1-20) Copyright © 2006 Ex- 
cerpta Medica, Inc. 
Key words: rabeprazole, hepatic disorders, cirrhosis, chronic hepatitis, 
upper gastrointestinal lesions, gastric ulcer, duodenal ulcer, reflux esophagitis, 
stomal ulcer. 
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INTRODUCTION 
Hepatic disorders are broadly classified based on progression to hepatitis 
(acute or chronic), cirrhosis, and hepatocellular carcinoma. 1 Cirrhosis is subclas- 
sifted as compensated cirrhosis and decompensated cirrhosis (hepatic insufficien- 
cy), depending on the presence or absence of overt jaundice, ascites, edema, 
and impairment of consciousness. 1 A cirrhotic liver (during decompensated 
stage) has reduced function, with particular reductions in drug-metabolizing 
activity and compromised activity to synthesize proteins, such as albumin, pos- 
sibly leading to increased unbound and total drug concentrations in the blood. 2 
Hepatic disorders cause reduced hepatic function and various complications 
(including subjective symptoms). Major complications of severe hepatic dis- 
ease include general malaise, fatigue, palmar erythema, spider angioma, pur- 
pura, jaundice, ascites, esophageal varices, and hepatic encephalopathy. 3 
Approximately 10% to 20% of patients with hepatic disorders (including cir- 
rhosis and chronic hepatitis) develop upper gastrointestinal (GO peptic 
lesions. 4,5 Reductions in gastric mucosal defensive factors 6and altered gastric 
acid secretion 7 have been associated with the development of peptic lesions in 
patients with hepatic disease. In these patients, peptic lesions are typically 
treated in the same manner as peptic ulcers uncomplicated by hepatic disease, 
using agents such as gastric secretion suppressants 8 and mucosal defensive 
factor enhancers. 9 Proton pump inhibitors (PPIs) are commonly used for the 
treatment of peptic lesions. However, despite their widespread use, PPIs have 
been associated with adverse drug reactions (ADRs) (incidence, -1%-5%), in- 
cluding elevated liver enzyme levels, x°,11 
Patients with cirrhosis experience a high frequency of GI lesions caused by 
congested blood circulation in the gastric mucosa, 12-14 decreased prostaglandin 
E 2 levels, decreased membrane potential in the gastric mucosa, 15,16 and excess 
secretion of gastric juice (during compensated cirrhosis stage). 17 According to 
study results reported at the 30th Annual Conference of the Japanese 
Gastroenterological Endoscopy Society, 18 patients with cirrhosis experience 
peptic complication at a higher rate compared with healthy individuals, with 
the incidence being 20% to 30% for redness and erosion, 15% to 20% for gastric 
ulcer, and -10% for duodenal ulcer. These peptic lesions are usually treated 
with various mucosal defensive factor enhancers, prostaglandins, histamine-H 2 
receptor antagonists, and PPIs. PPIs are often used for the treatment of in- 
tractable gastric/duodenal ulcers in cirrhotic patients. 
One PPI, rabeprazole sodium, was approved by the US Food and Drug 
Administration in 1999 for the short-term (4-8 weeks) treatment of erosive or 
ulcerative gastroesophageal reflex disease (GERD); symptomatic GERD; main- 
taining healing in patients with GERD; healing and symptomatic relief of duode- 
nal ulcers; long-term treatment of pathologic hypersecretory conditions, in- 
cluding Zollinger-Ellison syndrome; and the eradication of Helicobacter pylori 
in combination with amoxicillin and clarithromycin. Rabeprazole has been 
found to be efficacious in the treatment of gastric ulcer, duodenal ulcer, and 
CURRENT THERAPEUTIC RESEARCH 
GERD. 19,20 However, because many antiulcer drugs, including rabeprazole, 21 are 
metabolized in the liver, and because liver enzyme activity might be reduced in 
patients with hepatic diseases, ADRs might occur at a higher ate in these patients 
compared with healthy individuals. In the livers of patients with normal hepatic 
function, rabeprazole is rapidly metabolized after being absorbed from the diges- 
tive tract via the first-pass effect. In contrast, in patients with hepatic disease, ad- 
ministration of rabeprazole tablets has been reported to cause a prolonged tl/2, 
decreased total body clearance, 22and increased aminotransferase levels. 19,23 
Due to the hepatic metabolism ofPPIs, including rabeprazole, the debilitated state 
of patients with hepatic disease, and the possibility of ADRs, 19'21'23 any drug used 
in patients with complicated hepatic disease must be scrutinized. 
Based on a MEDLINE search for literature concerning rabeprazole use (key 
terms: rabeprazole, peptic lesion, and hepatic disease; years: 1997-2005), the tol- 
erability and effectiveness of this drug in patients with peptic lesions and 
underlying hepatic disease in routine clinical practice has not yet been clari- 
fied. We conducted the present survey to assess the tolerability and effective- 
ness of rabeprazole in patients with upper GI peptic lesions and coexisting 
hepatic disorders in routine clinical practice in Japan. 
PATIENTS AND METHODS 
This multicenter, open-label, practice-based, postmarketing surveillance inves- 
tigation was conducted at 15 medical institutions across Japan. The study pro- 
tocol was derived according to the principles of Good Post-Marketing Sur- 
veillance Practice. 24 Institutional review board approval of the study protocol 
was obtained from each participating institution. 
Inclusion and Exclusion Criteria 
Recruiting was performed using a central registration method to enroll 
patients who were confirmed as eligible using routine medical examination, en- 
doscopy, and histopathology from June 1998 to July 1999. Male and female pa- 
tients aged >18 years with endoscopically confirmed peptic lesions (including 
gastric ulcer, duodenal ulcer, stomal ulcer, and reflux esophagitis) and coexisting 
hepatic disease were eligible for enrollment. Patients receiving rabeprazole treat- 
ment or unable to receive drugs orally due to dysphagia or encephalopathy were 
excluded. Pregnant or breastfeeding patients were excluded. Before initiation of 
rabeprazole treatment, written informed consent was obtained from each patient. 
Study Drug Administration 
Patients received rabeprazole 10 or 20 mg PO (enteric-coated tablet) QD after a 
meal for 6 weeks for the treatment ofduodenal ulcer, or 8 weeks for gastric ulcer, 
stomal ulcer, and/or reflux esophagitis. During the treatment period, if improve- 
ment (based on the investigator's judgment using endoscopic findings and subjec- 
tive symptoms) was not achieved, the dose could be increased to 20 mg QD. 
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Because this study was conducted in the routine clinical practice setting, no 
restriction was placed on concomitant drugs. If concomitant drugs were used 
during the treatment period, the drug, dose, route of administration, and treat- 
ment duration were recorded in each patient's case-report form. 
Tolerability Assessment 
Patients underwent the following laboratory assessments before and after 
rabeprazole treatment: hematology and biochemistry (red and white blood cell 
counts; differentials [basophils, eosinophils, neutrophils, lymphocytes, and 
monocytes]; platelet count; hemoglobin concentration; hematocrit; and serum 
levels of aspartate and alanine aminotransferases, ~/-glutamyl transpeptidase 
[y-GTP], lactate dehydrogenase, total bilirubin, albumin, C-reactive protein, 
total cholesterol [TC], triglycerides [TG], blood urea nitrogen, serum creati- 
nine, and prothrombin time). 
All medically undesirable symptoms/findings that occurred after the start of 
treatment with rabeprazole were regarded as adverse vents (AEs), and classi- 
fied as ADRs if a causal relationship with rabeprazole could not be ruled out. 
Symptoms/findings and abnormal laboratory values were compared separately. 
Effects of demographic and clinical characteristics of patients on the occur- 
rence of ADRs were investigated. Direct patient questioning and spontaneous 
reporting were also used to assess tolerability. 
Effectiveness Assessment 
Improvement on Endoscopy 
Endoscopic examinations were performed before (baseline) and after (in 
a subset of patients, depending on their condition) the treatment period. 
Endoscopic findings were assessed according to the stage classification of 
Sakita and Miwa 25 for gastric, duodenal, and stomal ulcer, and reflux 
esophagitis according to the Los Angeles Classification, 26using the follow- 
ing scale: for gastric, duodenal, or stomal ulcer: 1 = stage A1 (active ulcer); 
2 = stage A2 (active ulcer); 3 = stage H1 (partially healed); 4 = stage H2 (par- 
tially healed); 5 -- stage $1 (completely healed); and 6 = stage $2 (completely 
healed); for reflux esophagitis: 1 = grade D (mucosal breaks that involve 
>-75% of the esophageal circumference); 2 = grade C (mucosal breaks that 
extend between the tops of 2 or more mucosal folds but that involve <75% 
of the esophageal circumference); 3 = grade B (>-1 mucosal breaks >5 mm); 
4 = grade A (>-1 mucosal breaks ~5 mm); and 5 = grade O (completely 
healed). 
Symptom Improvement 
Severity of subjective symptoms such as epigastric pain and heartburn was 
monitored before and after treatment. The severity of symptoms was assessed 
on a 4-point Likert scale (0 = none [-]; 1 = mild, occasionally symptomatic [_+]; 
2 = moderate, symptomatic [+]; and 3 = symptomatic and painful [++]). 
5 
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Global Improvement Rating Scale 
At the end of the treatment period, the effectiveness of rabeprazole was 
assessed using a global improvement rating, based on the changes over time in 
endoscopic findings and subjective symptoms, using a 5-point scale (0 = unassess- 
able; 1 = aggravated; 2 = unchanged; 3 = slightly improved; and 4 = improved). 
Subanalysis 
Subanalyses were conducted to determine the effectiveness of rabeprazole by 
calculating the proportions of patients with coexisting hepatic disorders (cirrho- 
sis [including hepatocellular carcinoma], chronic hepatitis, and other hepatic 
diseases [alcoholic hepatitis, fatty liver]) and by peptic lesion (gastric, duode- 
nal, and stomal ulcer; and reflux esophagitis) who achieved improvement. 
Statistical Analysis 
The tolerability analysis comprised all patients who received at least 1 dose 
of study drug. For laboratory values, all patients with complete data before and 
after treatment were included in the tolerability analysis. ADRs were assessed 
with 90% CIs of the incidence by separate calculation for symptoms and labora- 
tory abnormalities. The analysis was performed using the Fisher exact test for 
variables with 2 strata and by %2 test for those with >3 strata. For ADRs occur- 
ring in >5 patients, data were to be analyzed using the Fisher exact test regard- 
less of the number of strata. The analysis was carried out with significance level 
of 5% (2-sided); no adjustment was attempted for multiplicity. 
The effectiveness analysis included all patients with complete data before 
and after treatment. Changes in endoscopic scores before and after treatment 
were compared using the Wilcoxon signed rank test. The rate (95% CI) of com- 
plete healing (stage S1 or $2) at treatment completion was calculated. The rate 
(95% CI) of patients with a symptom rating of "none (-)" at treatment comple- 
tion was calculated. Patients with no symptoms at treatment initiation were 
excluded from the analysis. Changes in subjective symptom scores before and 
after treatment were compared using the Wilcoxon signed rank test. The rates 
(95% CI) of global improvement or aggravation (worsening of peptic lesions) 
were calculated. F distribution was used to calculate CI. 
RESULTS 
One hundred fourteen patients were enrolled in the study (tolerability analysis, 
108 patients; effectiveness analysis, 98 patients). Six patients were excluded 
from all analyses due to loss to follow-up (2 patients), protocol violations (3), 
and unavailable data (1). 
Tolerability 
Table I shows the demographic and clinical characteristics of the patients 
included in the tolerability analysis. Most patients were men (81 [75.0%]); the 
6 
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Table I. Demographic and clinical characteristics of the study 
patients (tolerability population; n = 108).* 
No. (%) of 
Item Patients 
Age group 
~39 y 7 (6.5) 
40-64 y 59 (54.6) 
>65 y 42 (38.9) 
Patient status 
Outpatients 52 (48.1) 
Inpatients 27 (25.0) 
In- -~ outpatients 28 (25.9) 
Out- ~ inpatients 1 (0.9) 
Sex 
Male 81 (75.0) 
Female 27 (25.0) 
Digestive tract disease 
Gastric ulcer 47 (43.5) 
Reflux esophagitis 38 (35.2) 
Duodenal ulcer 21 (19.4) 
Stomal ulcer 2 (1.9) 
Severity of 
digestive tract disease 
Mild 46 (42.6) 
Moderate 50 (46.3) 
Severe 12 (11.1) 
Relapse history 
First occurrence 70 (64.8) 
Relapse 32 (29.6) 
Unknown 6 (5.6) 
Hepatic disorder 
Cirrhosis t 70 (64.8) 
Chronic hepatitis 17 (15.7) 
Other 21 (19.4) 
Complication 
Yes 67 (62.0) 
No 41 (38.0) 
Allergic diathesis 
Yes 4 (3.7) 
No 104 (96.3) 
(continued) 
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Table I. (Continued) 
No. (%) of 
Item Patients 
Previous treatment with antiulcer agents 
Yes 69 (63.9) 
No 39 (36.1) 
Concomitant drugs 
Yes 93 (86.1) 
No 15 (13.9) 
Rabeprazole dose 
10 mg 89 (82.4) 
20 mg 17 (15.7) 
10 --~ 20 mg 1 (0.9) 
20 --~ 10 mg 1 (0.9) 
Treatment duration~ 
~14 d 15 (13.9) 
15-28 d 11 (10.2) 
29-42 d 20 (18.5) 
43-56 d 39 (36.1) 
:-57 d 23 (21.3) 
Baseline hepatic function~ 
Total bilirubin 
Normal (<1.6 mg/dL) 76 (70.4) 
Grade 1 (1.6-<3.0 mg/dL) 18 (16.7) 
Grade 2 or 3 (=-3.0 mg/dL) 5 (4.6) 
Not determined 9 (8.3) 
AST 
Normal (<50 U/L) 48 (44.4) 
Grade 1 (50-<100 U/L) 40 (37.0) 
Grade 2 or 3 (=,100 U/L) 1 3 (12.0) 
Not determined 7 (6.5) 
ALT 
Normal (<50 U/L) 57 (52.8) 
Grade 1 (50-<100 U/L) 31 (28.7) 
Grade 2 or 3 (=,100 U/L) 1 3 (12.0) 
Not determined 7 (6.5) 
AI-P 
Normal 60 (55.6) 
Grade 1 (1.25-<2.5 x ULN) 31 (28.7) 
Grade 2 or 3 (=-2.5 × ULN) 6 (5.6) 
Not determined 11 (10.2) 
(continued) 
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Table I. (Continued) 
No. (%) of 
Item Patients 
y-GTP 
Normal 56 (51.9) 
Grade 1 (1.5-<2.5 × ULN) 19 (1 7.6) 
Grade 2 or 3 (_>2.5 x ULN) 22 (20.4) 
Not determined 11 (10.2) 
LDH 
Normal 90 (83.3) 
Abnormal (>1.5 x ULN) 6 (5.6) 
Not determined 12 (11.1) 
Platelet count 
Normal (>100 x 10 ~ cells/IJL) 58 (53.7) 
Grade 1 (75-100 x 103 cells/IJL) 18 (16.7) 
Grade 2 or 3 (<75 x 103 cells/IJL) 22 (20.4) 
Not determined 10 (9.3) 
Albumin 
Normal 51 (47.2) 
Grade 1 (1.5-<2.5 x ULN) 23 (21.3) 
Grade 2 or 3 (>2.5 x ULN) 16 (14.8) 
Not determined 18 (16.7) 
AST = aspartate aminotransferase; ALT = alanine aminotransferase; AI-P = 
alkaline phosphatase; ULN = upper limit of normal; y-GTP = y-glutamyl 
transpeptidase; LDH = lactate dehydrogenase. 
*Percentages may not add to 100% due to rounding. 
tlncludes hepatocellular carcinoma. 
tFor patients with adverse drug reactions (ADRs), data were collected until 
the date of the onset of the ADR. 
§Classification based on the Criteria for Severity Grading of ADRs 27 and the 
criteria established for the survey of use status of rabeprazole tablets. 
mean age was 59.9 years. Patients aged 40 to 64 years accounted for the largest 
proportion (59 [54.6%]), followed by those aged ->65 years (42 [38.9%]). Patients 
with cirrhosis (including hepatocellular carcinoma) accounted for the majority 
(70 [64.8%]), followed by those with chronic hepatitis (17 [15.7%]). 
Rabeprazole tablets were administered at 10 mg/d to 90 (83.3%) patients and 
at 20 mg/d to 18 (16.7%) patients. 
Table II lists ADRs by patient. Of 108 patients, 11 (10.2%) (90% CI, 5.8%- 
16.3%) experienced 21 ADRs, as follows: metabolism and nutritional disorders 
in 3 patients, 5 events (elevated alkaline phosphatase l vel [3], elevated 
serum TG level [1], elevated serum TC or low-density lipoprotein cholesterol 
[LDL-C] level [1]); hepatic and biliary system disorders, 5 patients, 5 events 
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(elevated y-GTP level [3], elevated bilirubin level [1; serious], hepatic 
encephalopathy [1]); gastrointestinal system disorders, 4 patients, 5 events 
(loose stools [2], constipation [1], diarrhea [1], and epigastric pain [1]); central 
and peripheral nervous system disorders, 1 patient, 3 events (disorientation, 
dyslalia, and tremor [1 each]); leukocyte and reticuloendothelial system disor- 
ders, 1 patient, 1 event (eosinophilia); psychiatric disorder, 1 patient, 1 event 
(sleep disorder); and vascular (extracardiac) system disorder, 1 patient, 1 event 
(purpura). Five patients were counted in multiple categories, for a total of 
16 events. Among the ADRs, 6 serious reactions were observed in 2 patients, 1with 
elevated bilirubin and 1 with dyslalia, disorientation, tremor, sleep disorder, 
and hepatic encephalopathy. The outcome in these 2 patients with cirrhosis 
and hepatocellular carcinoma was recovery (dyslalia, disorientation, tremor, 
sleep disorder, and hepatic encephalopathy) or remission (elevated bilirubin) 
following the discontinuation of rabeprazole. 
The outcomes of the 21 ADRs were recovery or remission in 16 patients and 
unknown due to loss to follow-up in 5 (elevated levels of alkaline phosphatase; 
~/-GTP; serum TG, TC, and LDL-C; and eosinophilia). 
Administration of rabeprazole was discontinued in 5 patients due to the 
occurrence of the following ADRs: constipation (day 7); epigastric pain (day 2); 
dyslalia, disorientation, tremor, sleep disorder, and hepatic encephalopathy 
(day 22); diarrhea (day 3); and elevated alkaline phosphatase and y-GTP levels 
(day 11). 
Five ADRs in 1 patient required treatment (dyslalia, disorientation, tremor, 
sleep disorder, and hepatic encephalopathy); these ADRs were treated success- 
fully with flumazenil. One patient was an asymptomatic carrier of hepatitis B 
virus in whom duodenal ulcer and mild anemia developed on day 45 of treat- 
ment with rabeprazole 10 mg/d. This patient was excluded from the tolerability 
and effectiveness analyses. The anemia was treated successfully with sodium 
ferrous citrate. 
The incidence of symptoms/findings was 6/108 (5.6%) (90% CI, 2.45%-10.67%), 
and the incidence of abnormal aboratory values was 5/108 (4.6%) (90% CI, 
1.84%-9.49%). 
Some laboratory values deviated from the normal range, but no marked 
changes from baseline were observed in any patient. Laboratory values consid- 
ered ADRs were as follows: hematologic values, 1 patient, 1 event (mild eosin- 
ophilia); and liver function values, 4 patients, 4 events (mild elevated ~/-GTP 
level [3] and serious elevated bilirubin level [1]). Among them, outcomes of the 
elevated ~/-GTP level and eosinophilia were unknown due to loss to follow-up. All 
other abnormal aboratory values returned to normal or were improved after 
study completion. 
The incidence of ADRs was significantly higher in inpatients compared with 
outpatients (6 [22.2%] vs 5 [9.6%] patients; P < 0.045) and in patients with 
a treatment duration ~28 days compared with those who received treatment for 
>28 days (9 [34.6%] vs 2 [2.4%] patients; P< 0.001). No other demographic and 
11 
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clinical characteristics were found to have a significant effect on the incidence 
of ADRs. 
Of the 70 (64.8%) patients with cirrhosis (including hepatocellular carcino- 
ma), 40 (57.1%) patients had been treated with concomitant drugs to prevent 
ascites and/or impairment of consciousness and were thus considered to have 
decompensated cirrhosis. Two of them also had received anticancer agents 
(epirubicin hydrochloride, mitomycin C) to treat hepatocellular carcinoma. Of 
the 11/70 (15.7%) patients who experienced ADRs, 9 had cirrhosis. 
Effectiveness 
The demographic and clinical characteristics of the 98 patients included in 
the effectiveness analysis are shown in Table III. Patients aged 40 to 64 years 
accounted for the largest proportion (54 [55.1%]) and male patients were pre- 
dominant (74 [75.5%]). The prevalences of lesions in the 98 patients were as fol- 
lows: gastric ulcer, 45 (45.9%) patients; duodenal ulcer, 17 (17.3%); reflux 
esophagitis, 34 (34.7%); and stomal ulcer, 2 (2.0%). The prevalences of preexist- 
ing hepatic disorders were: cirrhosis, 62 (63.3%) patients 0ncluding 20 patients 
with hepatocelhlar carcinoma); chronic hepatitis, 16 (16.3%); and other, 20 
(20.4%). Rabeprazole was administered at 10 mg/d to 80 (81.6%) patients and at 
20 mg/d to 16 (16.3%) patients. The dose was changed in 2 (2.0%) patients dur- 
ing the course of the treatment. 
Improvement on Endoscopy 
Of the 98 patients included in the analysis of effectiveness, 33 (33.7%) patients 
with complete ndoscopic data before and after treatment with 10 or 20 mg 
were eligible for analysis. 
Endoscopic findings showed improvement in 30/33 (90.9%) patients. 
Changes in endoscopic assessment score before and after treatment are shown 
in Tables W and V. The healing rates of peptic lesions were: gastric ulcer, 
14/18 (77.8% [95% CI, 52.4%-93.6%]); duodenal ulcer, 3/5 (60.0% [95% CI, 14.7%- 
94.7%]) (Table IV); and reflux esophagitis, 4/9 (44.4% [95% CI, 13.7%-78.8%]) 
(Table V). Stratification by peptic lesion found significantly improved endo- 
scopic scores for gastric ulcer and reflux esophagitis (Table Vl). Of the 
3 (9.1%) patients without endoscopic improvement, 1 had gastric and duo- 
denal ulcers complicated by cirrhosis and hepatic encephalopathy (this 
patient was receiving concomitant NSAIDs), and 2 had reflux esophagitis and 
cirrhosis. 
Symptom Relief Rates 
The predominant symptoms were heartburn (56 [57.1%]) and epigastric pain 
(55 [56.1% ]). Both of these symptoms were significantly improved with rabepra- 
zole use. 
The relief rates of epigastric pain and heartburn were 47/55 (85.5%) and 
47/56 (83.9%), respectively. Improvement rates of epigastric pain and heartburn 
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Table III. Demographic and clinical characteristics of the study 
patients (effectiveness population; n = 98). 
Characteristic No. (%) of Patients 
Age group 
~39 y 7 (7.1) 
40-64 y 54 (55.1) 
~65 y 37 (37.8) 
Patient status 
Outpatients 46 (46.9) 
In- ~ outpatients 27 (27.6) 
Inpatients 24 (24.5) 
Out- -~ inpatients 1 (1.0) 
Sex 
Male 74 (75.5) 
Female 24 (24.5) 
Digestive tract disease 
Gastric ulcer 45 (45.9) 
Reflux esophagitis 34 (34.7) 
Duodenal ulcer 1 7 (17.3) 
Stomal ulcer 2 (2.0) 
Severity 
Mild 41 (41.8) 
Moderate 47 (48.0) 
Severe 10 (10.2) 
Relapse history 
First occurrence 65 (66.3) 
Relapse 28 (28.6) 
Unknown 5 (5.1) 
Hepatic disorder 
Cirrhosis* 62 (63.3) 
Chronic hepatitis 16 (16.3) 
Other 20 (20.4) 
Other complication t 
Yes 61 (62.2) 
No 37 (37.8) 
Previous treatment with anti-ulcer agents 
(all categories) 
Yes 64 (65.3) 
No 34 (34.7) 
Concomitant drugs 
Yes 84 (85.7) 
No 14 (14.3) 
(continued) 
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Table III. (Continued) 
Characteristic No. (%) of Patients 
Rabeprazole dose ~ 
10 mg 80 (81.6) 
20 mg 16 (16.3) 
10 mg --~ 20 mg 1 (1.0) 
20 mg --~ 10 mg 1 (1.0) 
Treatment duration 
~14 d 9 (9.2) 
15-28 d 11 (11.2) 
29-42 d 1 7 (17.4) 
43-56 d 40 (40.8) 
z57 d 21 (21.4) 
*includes 20 patients with hepatocellular carcinoma. 
tlncludes esophageal varices, hypertension, and diabetes mellitus. 
~Percentages do not total 100% due to rounding. 
Table IV. Patients w i th  healed ulcers on endoscopy after up to 8 weeks of t reatment  
w i th  rabeprazole 10 or 20 mg/d  in patients w i th  upper gastrointestinal pep- 
tic lesions complicated by under ly ing hepatic disease (effectiveness popula- 
t ion; n = 98). 
Ulcer Type/ 
Baseline Stage* 
Posttreatment Ulcer Stage* 
n A2 H1 H2 $1 $2 
Gastric t
A1 7 
A2 8 
H1 2 
H2 1 
Duodenal t
A1 3 
A2 2 
0 1 0 4 2 
1 1 1 3 2 
0 0 0 1 1 
0 0 0 0 1 
0 1 2 0 
1 0 0 1 
*Endoscopic findings were assessed according to the stage classification of Sakita and Miwa 2s for gas- 
tric, duodenal, and stomal ulcer, and reflux esophagitis according to the Los Angeles Classification, 26 
using the following scale: 1 = stage A1 (active ulcer); 2 = stage A2 (active ulcer); 3 = stage H1 (par- 
tially healed); 4 = stage H2 (partially healed); 5 = stage $1 (completely healed); and 6 = stage $2 
(completely healed). 
tEndoscopic healing rate (95% CI) = (No. of patients with disease improved to stage $1 or S2)/(No. 
of patients eligible for analysis) × 100 = 77.8% (52.4%-93.6%) (gastric ulcer) and 60.0% (14.7%- 
94.7%) (duodenal ulcer). 
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Table V. Patients wi th healed reflux esophagitis on endoscopy after up to 
8 weeks of t reatment  wi th rabeprazole 10 or 20 mg/d  in patients 
wi th  upper gastrointestinal peptic lesions complicated by under- 
lying hepatic disease (effectiveness populat ion;  n = 98).* 
Posttreatment MLAC Grade t
Baseline 
MLAC Grade t n C B A D 
D 3 1 0 0 2 
C 2 0 0 2 0 
B 3 0 2 0 1 
A 1 0 0 0 1 
MLAC = Modified Los Angeles classification. 
*Endoscopic healing rate (No. of patients with disease improved to grade O/No. of 
patients eligible for analysis) × 100 = 44.4% (95% CI, 13.7%-78.8%). 
tMLAC26:1 = grade D (mucosal breaks that involve ~75% of the esophageal circumference); 
2 = grade C (mucosal breaks that extend between the tops of =,2 mucosal folds but that 
involve <75% of the esophageal circumference); 3 = grade B (~1 mucosal breaks 
>5 mm); 4 = grade A (~1 mucosal breaks ~5 mm); and 5 = grade O (completely healed). 
Table VI. Changes in endoscopic scores before and after t reatment  wi th 
rabeprazole 10 or 20 mg/d  for up to 8 weeks in patients wi th 
upper gastrointestinal peptic lesions complicated by underlying 
hepatic disease (effectiveness populat ion;  n = 98). Values are no. 
of patients. 
Change in Score* 
Disease 0 +1 +2 +3 +4 +5 
Gastric ulcer 1 1 4 4 6 2 
Duodenal ulcer - 1 - 1 3 - 
Stomal ulcer - - - 1 - - 
Reflux esophagitis 2 2 3 - 2 - 
All diseases 3 4 7 6 11 2 
*The larger the change in the score in the plus direction, the larger the extent of the 
improvement. 
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combined were 63/80 (78.8%) and 15/16 (93.8%) in the 10- and 20-mg/d groups, 
respectively. The rates of epigastric pain relief were 35/43 (81.4%) and 10/10 
(100%) in the 10- and 20-mg/d groups, respectively. The heartburn relief rates 
were 38/47 (80.9%) and 9/9 (100%) in the 10- and 20-mg/d groups, respectively. 
The improvement rates by peptic lesion were as follows: gastric ulcer, 36/45 
(80.0%); duodenal ulcer, 15/17 (88.2%); stomal ulcer, 2/2 (100.0%); and reflux 
esophagitis, 27/34 (79.4%). 
The improvement rates by preexisting hepatic disorders were as follows: cir- 
rhosis (including hepatocellular carcinoma), 49/62 (79.0%); chronic hepatitis, 
11/16 (68.8%); and other hepatic diseases (alcoholic hepatitis, fatty liver), 20•20 
(100%). 
Global Improvement Rating 
Of 98 patients, 80 (81.6%) (95% CI, 72.5%-88.7%) achieved improvement, 16 
(16.3%) achieved slight improvement, and 2 (2.0%) were considered nonassess- 
able because of the short duration of treatment or insufficient data available for 
assessment. None of the patients experienced aggravated peptic lesion (95% CI, 
0%-0.4%). 
Improvement rates by underlying hepatic disease were as follows: cirrhosis 
(including hepatocellular carcinoma), 49/62 (79.0%); chronic hepatitis, 11/16 
(68.8%); and other hepatic disorders (alcoholic hepatitis, fatty liver), 20/20 
(100.0%). These differences were not statistically significant. No other demo- 
graphic or clinical characteristics were found to affect the improvement rate 
(Table VII). 
DISCUSSION 
Suzuki et al 3 reported that the rates of cirrhosis complicated by spider angioma, 
ascites, esophageal varices (stage II or more), and hepatic encephalopathy 
were 45.0%, 30.8%, 46.3%, and 15.6%, respectively. However, in our study, these 
complications were classified as ADRs if the onset was during rabeprazole treat- 
ment (as in 1 patient with underlying cirrhosis who experienced purpura and 
hepatic encephalopathy). 
Of the 108 patients included in the tolerability analysis, 10.2% of patients 
experienced 21 ADRs. When tolerability results obtained in the present survey 
were compared with those obtained uring the clinical development of rabepra- 
zole (N = 1244), 28 the incidences of adverse symptoms and abnormal laboratory 
values observed were 1.8% (90% CI, 1.2%-2.5%) and 6.6% (90% CI, 5.28%--8.12%), 
respectively, compared with 5.6% (90% CI, 2.5%-10.7%) and 4.6% (90% CI, 
1.8%-9.5%) in the present study. 
Investigation of the association between baseline demographic and clinical 
characteristics and the incidence of ADRs revealed higher incidences observed 
in inpatients and in those who received short-term treatment. The higher inci- 
dence of ADRs observed in hospitalized patients uggests that the frequency is
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associated with more severe hepatic disorders: 59.3% inpatients in the present 
survey had decompensated cirrhosis, compared with 19.2% outpatients. 
Improvement on endoscopy was found in 90.9% patients (P < 0.001). Of the 
3 patients without improvement, all had cirrhosis and 1 was receiving concomi- 
tant NSAIDs. The patient receiving NSAIDs showed improvement in subjective 
symptoms during treatment with rabeprazole, but the lack of endoscopic 
improvement could have been due to NSAID use. Subjective symptoms resolved 
during treatment in 1 patient with reflux esophagitis who had type C cirrhosis 
complicated by depression and hepatocellular carcinoma. This patient was lost 
to follow-up after 3 weeks; thus, improvement could not be assessed. Another 
patient with reflux esophagitis had cirrhosis complicated by esophageal varices 
and discontinued rabeprazole administration after 2 weeks. 
The relief rates of subjective symptoms (85.5% and 83.9% for epigastric pain 
and heartburn combined and heartburn alone, respectively) were comparable 
to those obtained in previous tudies. 19,29 
The 81.6% global improvement rate was lower compared with that found in a 
previous Phase II study 19 of rabeprazole 10 and 20 mg/d in healthy subjects with 
lesions but no underlying hepatic disease. The rates of improvement by peptic 
lesion in this study (100.0%, 88.2%, 80.0%, and 79.4% for stomal, duodenal, and 
gastric ulcer; and reflux esophagitis, respectively) were lower compared with those 
found in the Phase II study 19 (100%, 100%, and 96.9% for gastric ulcer treated with 
rabeprazole 20 mg/d, duodenal ulcer treated with rabeprazole 10 or 20 mg/d, and 
gastric ulcer treated with rabeprazole 10 mg/d, respectively). 19 These discrepan- 
cies might be attributable to the fact that 64.8% of patients enrolled in the present 
study had cirrhosis, and that factors other than gastric acid secretion might have 
contributed to the emergence ofpeptic lesions in patients with preexisting hepatic 
disease. 18 Some patients discontinued the administration of the drug because of 
AEs or difficulty receiving the medication orally (in patients with severe hepatic 
disease) (treatment for <2 weeks in -20% of the patients). These short treatment 
durations might have contributed to the lower global improvement rate observed 
in the present study compared with that in the Phase II study. 19 
The global improvement rates stratified by underlying hepatic disorder were 
79.0%, 68.8%, and 100.0% for cirrhosis (including hepatocellular carcinoma), 
chronic hepatitis, and other disorders (alcoholic hepatitis, fatty liver), respec- 
tively. Higher rates of improvement were found in hepatic diseases in which 
hepatic function is retained, including alcoholic hepatitis and fatty liver. 
The results of this postmarketing surveillance study suggest hat caution 
should be exercised when treatment with rabeprazole (10 or 20 mg) is initiated 
in Japanese patients with severe hepatic dysfunction. 
CONCLUSION 
The results of this study in Japanese patients with hepatic disease suggest hat 
rabeprazole was well tolerated and effective for the treatment of upper GI pep- 
tic lesions. 
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